We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain AMN Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
AMN Healthcare's growth prospects are supported by strong staffing demand, MSP opportunities and technology.
Nurse and Allied revenues rose 27% in Q3, with AMN projecting 13-15% underlying growth in Q4.
Visa delays, pricing pressures and weakness in Physician and Technology businesses pose risks.
AMN Healthcare Services, Inc. (AMN - Free Report) is well-poised for growth in the coming quarters, courtesy of its broad array of services. The optimism is led by strong momentum in its Managed Services Program (MSP), favorable healthcare staffing demand, diversified workforce solutions, and investments in technology and AI-driven platforms. However, visa appointment delays, pricing pressure and segment weakness remain headwinds.
Shares of this Zacks Rank #3 (Hold) company have surged 140.5% year to date, outperforming the industry’s 6.1% decline and the S&P 500’s 10.2% rise.
This renowned player in the healthcare total talent services space has a market capitalization of $1.46 billion. The company projects 184.6% year-over-year earnings growth for 2026. AMN Healthcare surpassed the Zacks Consensus Estimate in the trailing four quarters, delivering an average earnings surprise of 177.1%.
Image Source: Zacks Investment Research
Factors Favoring AMN Stock
Nurse and Allied Staffing Demand: Demand for healthcare staffing is improving, supported by higher patient volumes, persistent vacancies and staff turnover at healthcare facilities. Providers are increasingly recognizing the flexibility and cost effectiveness of supplemental staffing amid limited permanent hiring.
In third-quarter 2026, AMN Healthcare's Nurse and Allied Solutions revenues increased 27% year over year to $460 million, including 21% growth in Travel Nurse volume and 12% growth in Allied volume. Combined Nurse and Allied volume rose 16%, while demand increased 70% from its February low through October. Education volume also grew more than 25%. Improved recruiting technology, faster placements and 24/7 execution are helping AMN capture higher demand. Management expects underlying Nurse and Allied revenues, excluding labor disruption activity, to grow 13-15% year over year in the fourth quarter. Sustained volume growth could support AMN's revenue recovery.
Opportunities in MSP Solutions: Healthcare providers are increasingly seeking workforce partners that can deliver comprehensive talent solutions, technology capabilities and greater visibility into staffing requirements. AMN's Managed Services Programs (MSPs) are well positioned to benefit from this shift by helping healthcare organizations manage workforce needs across multiple staffing suppliers.
For the third consecutive quarter, more than half of AMN's total sales pipeline consisted of MSP opportunities. Management reported strong client retention and a sequential increase in its pipeline. Healthcare organizations are seeking partners willing to share workforce risks and commit to service-level agreements for staffing fulfillment. AMN's established client relationships and broad workforce capabilities could help it secure additional MSP contracts, strengthen client relationships and capture a larger share of healthcare staffing demand.
Technology Investments and Diversified Solutions: AMN continues to invest in technology and operational improvements to enhance recruiter productivity, accelerate placements and expand its workforce solutions portfolio. Its WorkWise platform supports data-driven workforce optimization, while the Passport app for healthcare professionals has added natural-language job search capabilities, which management said is positively influencing clinician supply.
The company is improving its Locum Tenens operations through automation, technology enablement and faster fulfillment processes. Search revenues increased 15% year over year in the third quarter, reflecting strength in executive search and physician permanent placement. These initiatives provide multiple growth opportunities beyond traditional staffing and could improve operating efficiency and profitability over time.
Downsides of AMN Stock
Pricing and Competitive Pressures: Despite improving staffing demand, AMN continues to face intense competition across its businesses. Nurse and Allied gross margins remained relatively stable as average bill rates were flat year over year. Management noted that bill rates have remained stable for 18 months, while the cost premium for travelers over permanent clinical staff has declined to historically low levels.
Technology and Workforce Solutions revenues fell 9% year over year in the third quarter. Language Services pricing declined 9%, while VMS revenues decreased 11%. Competitive pricing, particularly in language services and staffing, could continue to constrain revenue growth and margin expansion.
Visa Appointment Delays: AMN's international nurse business faces near-term challenges due to ongoing delays in embassy visa appointments. Although international nurse revenues increased 32% year over year in the third quarter, limited appointment availability is expected to constrain new placements in 2027. Management anticipates a low-teens sequential decline in international revenues in the fourth quarter, followed by another smaller step-down in the first quarter. Even after appointments resume, it takes approximately four to five months to bring clinicians to the ground. Prolonged delays could therefore restrict international staffing growth and offset strength in domestic Nurse and Allied operations.
Weakness in Physician and Technology Businesses: Several AMN businesses continue to face operating challenges despite improving overall demand. Physician and Leadership Solutions revenues declined 4% year over year to $171 million in the third quarter, while Locum Tenens revenues fell 5%. Management expects the segment's fourth-quarter revenues to decline 5-7% year over year, with operational improvements expected to support a return to growth during 2027.
Technology and Workforce Solutions revenues also reflected pricing pressure in Language Services and lower platform volume in VMS. Although AMN expects its new global workforce model to improve Language Services margins beginning in the first half of 2027, the ongoing transitions and weak segment performance could weigh on growth in the near term.
AMN Healthcare has been witnessing a positive estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its earnings per share has improved 16.6% to $3.87.
The Zacks Consensus Estimate for fourth-quarter 2026 revenues and earnings per share is pegged at $663.1 million and 17 cents, respectively, suggesting 11.4% and 22.7% declines from the year-ago reported numbers.
Key Picks
Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Retain AMN Stock in Your Portfolio for Now
Key Takeaways
AMN Healthcare Services, Inc. (AMN - Free Report) is well-poised for growth in the coming quarters, courtesy of its broad array of services. The optimism is led by strong momentum in its Managed Services Program (MSP), favorable healthcare staffing demand, diversified workforce solutions, and investments in technology and AI-driven platforms. However, visa appointment delays, pricing pressure and segment weakness remain headwinds.
Shares of this Zacks Rank #3 (Hold) company have surged 140.5% year to date, outperforming the industry’s 6.1% decline and the S&P 500’s 10.2% rise.
This renowned player in the healthcare total talent services space has a market capitalization of $1.46 billion. The company projects 184.6% year-over-year earnings growth for 2026. AMN Healthcare surpassed the Zacks Consensus Estimate in the trailing four quarters, delivering an average earnings surprise of 177.1%.
Image Source: Zacks Investment Research
Factors Favoring AMN Stock
Nurse and Allied Staffing Demand: Demand for healthcare staffing is improving, supported by higher patient volumes, persistent vacancies and staff turnover at healthcare facilities. Providers are increasingly recognizing the flexibility and cost effectiveness of supplemental staffing amid limited permanent hiring.
In third-quarter 2026, AMN Healthcare's Nurse and Allied Solutions revenues increased 27% year over year to $460 million, including 21% growth in Travel Nurse volume and 12% growth in Allied volume. Combined Nurse and Allied volume rose 16%, while demand increased 70% from its February low through October. Education volume also grew more than 25%. Improved recruiting technology, faster placements and 24/7 execution are helping AMN capture higher demand. Management expects underlying Nurse and Allied revenues, excluding labor disruption activity, to grow 13-15% year over year in the fourth quarter. Sustained volume growth could support AMN's revenue recovery.
Opportunities in MSP Solutions: Healthcare providers are increasingly seeking workforce partners that can deliver comprehensive talent solutions, technology capabilities and greater visibility into staffing requirements. AMN's Managed Services Programs (MSPs) are well positioned to benefit from this shift by helping healthcare organizations manage workforce needs across multiple staffing suppliers.
For the third consecutive quarter, more than half of AMN's total sales pipeline consisted of MSP opportunities. Management reported strong client retention and a sequential increase in its pipeline. Healthcare organizations are seeking partners willing to share workforce risks and commit to service-level agreements for staffing fulfillment. AMN's established client relationships and broad workforce capabilities could help it secure additional MSP contracts, strengthen client relationships and capture a larger share of healthcare staffing demand.
Technology Investments and Diversified Solutions: AMN continues to invest in technology and operational improvements to enhance recruiter productivity, accelerate placements and expand its workforce solutions portfolio. Its WorkWise platform supports data-driven workforce optimization, while the Passport app for healthcare professionals has added natural-language job search capabilities, which management said is positively influencing clinician supply.
The company is improving its Locum Tenens operations through automation, technology enablement and faster fulfillment processes. Search revenues increased 15% year over year in the third quarter, reflecting strength in executive search and physician permanent placement. These initiatives provide multiple growth opportunities beyond traditional staffing and could improve operating efficiency and profitability over time.
Downsides of AMN Stock
Pricing and Competitive Pressures: Despite improving staffing demand, AMN continues to face intense competition across its businesses. Nurse and Allied gross margins remained relatively stable as average bill rates were flat year over year. Management noted that bill rates have remained stable for 18 months, while the cost premium for travelers over permanent clinical staff has declined to historically low levels.
Technology and Workforce Solutions revenues fell 9% year over year in the third quarter. Language Services pricing declined 9%, while VMS revenues decreased 11%. Competitive pricing, particularly in language services and staffing, could continue to constrain revenue growth and margin expansion.
Visa Appointment Delays: AMN's international nurse business faces near-term challenges due to ongoing delays in embassy visa appointments. Although international nurse revenues increased 32% year over year in the third quarter, limited appointment availability is expected to constrain new placements in 2027. Management anticipates a low-teens sequential decline in international revenues in the fourth quarter, followed by another smaller step-down in the first quarter. Even after appointments resume, it takes approximately four to five months to bring clinicians to the ground. Prolonged delays could therefore restrict international staffing growth and offset strength in domestic Nurse and Allied operations.
Weakness in Physician and Technology Businesses: Several AMN businesses continue to face operating challenges despite improving overall demand. Physician and Leadership Solutions revenues declined 4% year over year to $171 million in the third quarter, while Locum Tenens revenues fell 5%. Management expects the segment's fourth-quarter revenues to decline 5-7% year over year, with operational improvements expected to support a return to growth during 2027.
Technology and Workforce Solutions revenues also reflected pricing pressure in Language Services and lower platform volume in VMS. Although AMN expects its new global workforce model to improve Language Services margins beginning in the first half of 2027, the ongoing transitions and weak segment performance could weigh on growth in the near term.
AMN Healthcare Services Inc Price
AMN Healthcare Services Inc price | AMN Healthcare Services Inc Quote
Estimate Trend
AMN Healthcare has been witnessing a positive estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its earnings per share has improved 16.6% to $3.87.
The Zacks Consensus Estimate for fourth-quarter 2026 revenues and earnings per share is pegged at $663.1 million and 17 cents, respectively, suggesting 11.4% and 22.7% declines from the year-ago reported numbers.
Key Picks
Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.